Project

A. SN-38 Nano-Micelle Injectable Drug Product (late Preclinical study)
B. An Cancer Drug (Micelle) for Breast Cancer
C. Intratumoral Injectable Technology for Anti-Cancer Drugs

Project Summary

SN BioScience developed innovative new DDS (Drug Delivery System) for cytotoxic cancer drug, such as paclitaxel, docetacel and SN-38 (active metabolite of IRINOTECAN). Double micelle technology we developed is a kind of platform technology for hardly soluble new drug candidate as well as commerciallized drug product which have safety or formulations issues.

Business Model

A. Development of Innovative Drug Delivery System (DDS)
B. Strategic Development of Orphan Drug for Cancer
C. Licensing In and Out

Main Achievements

A. Investment from angel investor (~0.5M USD)
B. Patent submission (KR)
C. Contract with cGMP CMO
D. Ongoing preclinical study